Arcutis
Stock
Stock
Ticker: ARQT
ARQT
Price
Price
CHART BY
Frequently asked questions
What is Arcutis's market capitalization?
The market capitalization of Arcutis is $3.62B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Arcutis's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Arcutis is 139.16. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Arcutis?
Arcutis's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.207. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Arcutis's stock?
Currently, 8 analysts cover Arcutis's stock, with a consensus target price of $38.38. Analyst ratings provide insights into the stock's expected performance.
What is Arcutis's revenue over the trailing twelve months?
Over the trailing twelve months, Arcutis reported a revenue of $463.98M.
What is the EBITDA for Arcutis?
Arcutis's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $37.20M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Arcutis?
Arcutis has a free cash flow of $39.15M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Arcutis have, and what sector and industry does it belong to?
Arcutis employs approximately 354 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Arcutis's shares?
The free float of Arcutis is 109.51M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.62B
- EPS (TTM)
- $0.207
- Free Float
- 109.51M
- P/E ratio (TTM)
- 139.16
- Revenue (TTM)
- $463.98M
- EBITDA (TTM)
- $37.20M
- Free Cashflow (TTM)
- $39.15M
Pricing
- 52W span
- $19.30$31.75
Analyst Ratings
The price target is $38.38 and the stock is covered by 8 analysts.
Buy
7
Hold
1
Sell
0
Information
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
- Employees
- 354
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- ARQT
Fundamentals & EOD data from FactSet